Topics

Long-Term Data Supports Safety of Gilead's and Galapagos' JAK Inhibitor

20:00 EDT 10 Oct 2019 | BioSpace

As Gilead Sciences and its development partner Galapagos NV eye filing a New Drug Application with the U.S. Food and Drug Administration for its JAK inhibitor filgotinib, the companies’ hopes have been boosted by new 52-week safety data.

Original Article: Long-Term Data Supports Safety of Gilead's and Galapagos' JAK Inhibitor

NEXT ARTICLE

More From BioPortfolio on "Long-Term Data Supports Safety of Gilead's and Galapagos' JAK Inhibitor"

Quick Search

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...